(R)-(-)-Ibuprofen (Synonyms: (-)-Ibuprofen) |
| Catalog No.GC13030 |
Inhibitor of Cox-1 and Cox-2
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51146-57-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, inactive on COX, inhibits NF-κB activation; (R)-(-)-Ibuprofen exhibits anti-inflammatory and antinociceptive effects.
(R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, with no inhibitory effect on COX, but is involved in pathways of lipid metabolism and is incorporated into triglycerides along with endogenous fatty acids[1]. (R)-(-)-Ibuprofen (1 μM) significantly reduces NF-κB activation and completely prevents NF-κB induction at 10 μM. (R)-(-)-Ibuprofen inhibits NF-κB luciferase activity with an IC50 of 121.8 μM, weaker than that of S(+)-ibuprofen (IC50, 61.7 μM). Furthermore, (R)-(-)-Ibuprofen (10 mM) has no effect on HSF[2].
References:
[1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.
[2]. Scheuren N, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *